Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

PDT Plus Vitamin D3 for Anal Dysplasia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02698293
Recruitment Status : Recruiting
First Posted : March 3, 2016
Last Update Posted : March 25, 2019
Sponsor:
Information provided by (Responsible Party):
Abramson Cancer Center of the University of Pennsylvania

Brief Summary:
This is a phase I dose escalation study of photodynamic therapy (PDT) for the treatment of patients with pre-malignant tumors and superficial microinvasive disease of the anal canal and/or perianal skin. All subjects (a maximum of 12) will be given the photosensitizer ALA orally followed by the administration of red light (629-635 nm) to the tumor from a laser. The dose of ALA will be 40 mg/kg administered approximately 4-6 hours before light administration. There will be two levels of light dose: 50 and 100 J/cm2, 3-6 patients in each. Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT. Patients will be observed for 30 days for the development of DLT. Patients will be followed up for 24 months for additional toxicity and efficacy data collection.

Condition or disease Intervention/treatment Phase
Anal Dysplasia Carcinoma in Situ Drug: Gliolan Drug: Vitamin D3 cholecalciferol) Other: Photodynamic Therpay Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Photodynamic Therapy (PDT) Plus Vitamin D3 for High-grade Anal Dysplasia and Microinvasive Anal Cancer
Estimated Study Start Date : April 1, 2019
Estimated Primary Completion Date : September 1, 2019
Estimated Study Completion Date : April 1, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitamin D

Arm Intervention/treatment
Experimental: Cohort 1

5-aminolevulinic acid hydrochloride (Gliolan), orally, 40 mg/kg administered approximately 4-6 hours before light administration. There will be two levels of light dose: 50 and 100 J/cm2. Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.

Total duration of drug product administration (including any open-label lead-in, if applicable).

Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.

None This is a phase I dose escalation study, with two levels of light dose. The design is cohorts of 3s. Light at 50 Joules and Light at 100 joules There are pre-defined DLTs.

Drug: Gliolan
orally, 40 mg/kg 4-6 hours prior to light application
Other Name: ALA

Drug: Vitamin D3 cholecalciferol)
Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.
Other Name: Natures Made Vitamin D3

Other: Photodynamic Therpay

Approximately 4-6 hours after photosensitizer administration, activating light will be applied.

The target mucosal lesion will be identified based on the initial clinical evaluation. Treatment light will be generated using a Modulight ML7710-630-6K diode laser, This laser produces up to 6W total power, with a peak wavelength of 630nm and 90% of laser power within 630-633 nm.

The light fluence (doses) will be 50 and 100 Joules per square centimeter.

Other Name: PDT

Experimental: Cohort 2

5-aminolevulinic acid hydrochloride (Gliolan), orally, 40 mg/kg administered approximately 4-6 hours before light administration. There will be two levels of light dose: 50 and 100 J/cm2. Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT Total duration of drug product administration (including any open-label lead-in, if applicable).

Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.

None This is a phase I dose escalation study, with two levels of light dose. The design is cohorts of 3s. Light at 50 Joules and Light at 100 joules There are pre-defined DLTs.

Drug: Gliolan
orally, 40 mg/kg 4-6 hours prior to light application
Other Name: ALA

Drug: Vitamin D3 cholecalciferol)
Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.
Other Name: Natures Made Vitamin D3

Other: Photodynamic Therpay

Approximately 4-6 hours after photosensitizer administration, activating light will be applied.

The target mucosal lesion will be identified based on the initial clinical evaluation. Treatment light will be generated using a Modulight ML7710-630-6K diode laser, This laser produces up to 6W total power, with a peak wavelength of 630nm and 90% of laser power within 630-633 nm.

The light fluence (doses) will be 50 and 100 Joules per square centimeter.

Other Name: PDT

Experimental: Cohort 3

5-aminolevulinic acid hydrochloride (Gliolan), orally, 40 mg/kg administered approximately 4-6 hours before light administration. There will be two levels of light dose: 50 and 100 J/cm2. Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT Total duration of drug product administration (including any open-label lead-in, if applicable).

Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.

None This is a phase I dose escalation study, with two levels of light dose. The design is cohorts of 3s. Light at 50 Joules and Light at 100 joules There are pre-defined DLTs.

Drug: Gliolan
orally, 40 mg/kg 4-6 hours prior to light application
Other Name: ALA

Drug: Vitamin D3 cholecalciferol)
Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.
Other Name: Natures Made Vitamin D3

Other: Photodynamic Therpay

Approximately 4-6 hours after photosensitizer administration, activating light will be applied.

The target mucosal lesion will be identified based on the initial clinical evaluation. Treatment light will be generated using a Modulight ML7710-630-6K diode laser, This laser produces up to 6W total power, with a peak wavelength of 630nm and 90% of laser power within 630-633 nm.

The light fluence (doses) will be 50 and 100 Joules per square centimeter.

Other Name: PDT




Primary Outcome Measures :
  1. Number of adverse events [ Time Frame: 18 months ]
    DLTs have been defined



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • A histological or cytological diagnosis of high-grade dysplasia or carcinoma in-situ, within past 4 months.
  • Premalignant lesions containing focal microinvasion are eligible when:

    • Surgery is not clinically mandated.
    • Subjects with medical conditions precluding surgery.
    • Subjects whose lesions cannot be completely resected based on size or location, or where significant functional morbidity would be anticipated with further surgery.
    • Patients refuse surgery.
  • The justification for inclusion of patients with microinvasive disease is based reports demonstrating the ability of photodynamic therapy to successfully treat both dysplasia and T1 squamous cell carcinoma of the anal canal
  • HPV positive by Cobas or other cytological assays within past 4 months
  • Documented HIV positivity
  • Patients must be on highly active anti-retroviral therapy with a CD4 count >200 for the past 12 months
  • Viral load <200 for 12 months for the past 12 months
  • ECOG performance status of 0-1.
  • 18 years of age or older.
  • Study subjects capable of providing informed consent.
  • Women of childbearing potential and men must agree to use a medically accepted method of birth control from the time they sign consent and until one month after receiving ALA

Exclusion Criteria:

  • Study subjects in whom the lesion has invasive squamous cell carcinoma of the anal cavity which is clinically appreciable.
  • Clinically occult microinvasive squamous cell carcinoma of the anal cavity which is not focal.
  • Study subjects who are pregnant or lactating .
  • Study subjects who have a platelet count of less than 100,000/cubic mm.
  • Study subjects with elevated aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, or total bilirubin levels >2X normal or a history of chronic liver disease or cirrhosis of the liver.
  • Significant cardiovascular history that would put the study subject at risk from hypotension that may occur with ALA
  • Study subjects with porphyria or hypersensitivity to porphyrins.
  • Administration of the following compounds: tetracyclines, sulfonamides, fluoroquinolones within 48 hours, or hypericin extracts within a week prior to light administration.
  • Study subjects with abnormal baseline creatinine level or diagnosed kidney disease.
  • Treatment with 5-FU, Imiquimod, trichloroacetic acid or ablative therapy within the previous month.
  • Study subjects who have a medical history of immune suppression. This will include patients with a past transplantation requiring ongoing immunosuppressive medications.
  • A history of sarcoidosis, hyperphosphatemia, or known kidney stones

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02698293


Contacts
Layout table for location contacts
Contact: Sally McNulty, RN 215-662-7720 Sally.McNulty@uphs.upenn.edu
Contact: Susan Prendergast, RN 215-662-4267 susan.prendergast@uphs.upenn.edu

Locations
Layout table for location information
United States, Pennsylvania
Abramson Cancer Center of the University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Sally McNulty, RN    215-662-7720    sally.mcnulty@uphs.upenn.edu   
Principal Investigator: Edgar Ben-Josef, MD         
Sponsors and Collaborators
Abramson Cancer Center of the University of Pennsylvania
Investigators
Layout table for investigator information
Principal Investigator: Edgar Ben-Josef, MD Abramson Cancer Center of the University of Pennsylvania

Layout table for additonal information
Responsible Party: Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Identifier: NCT02698293     History of Changes
Other Study ID Numbers: UPCC 08216
First Posted: March 3, 2016    Key Record Dates
Last Update Posted: March 25, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma in Situ
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Vitamin D
Ergocalciferols
Cholecalciferol
Vitamins
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents